CD109抗原在胶质瘤中的作用

doi:10.16352/j.issn.1001-6325.2024.12.1731

基础医学与临床 ›› 2024, Vol. 44 ›› Issue (12): 1731-1735.doi: 10.16352/j.issn.1001-6325.2024.12.1731

CD109抗原在胶质瘤中的作用

周平慧¹, 曹思捷¹, 岳栋², 董凤云^3*

1.济宁医学院临床医学院, 山东济宁 272067;
济宁医学院附属医院 2.泌尿外科;
3.检验科, 山东济宁 272029

收稿日期:2024-03-29 修回日期:2024-06-04 出版日期:2024-12-05 发布日期:2024-11-26
通讯作者: ^*dong.fengyun@163.com
基金资助:
山东省中医药科技项目(Q-2022135);高层次科研项目培育计划项目(JYGC2022 FKJ002);济宁市重点研发计划项目(2023YXNS116)

The role of CD109 antigen in glioma

ZHOU Pinghui¹, CAO Sijie¹, YUE Dong², DONG Fengyun^3*

1. Department of Clinical Medicine, Jining Medical University, Jining 272067;
2. Department of Urology;
3. Department of Laboratory Medicine, Affiliated Hospital of Jining Medical University, Jining 272029, China

Received:2024-03-29 Revised:2024-06-04 Online:2024-12-05 Published:2024-11-26
Contact: ^*dong.fengyun@163.com

摘要/Abstract

摘要： 白细胞分化抗原CD109是一种糖基化磷脂酰基醇(GPI)相关的细胞表面抗原,属于含α-2巨球蛋白/C3、C4和C5超家族的复合物,是转化生长因子β(TGF)-β/Smads共受体。CD109调控胶质瘤的发生发展,与胶质瘤的耐药及复发密切相关。作为细胞膜蛋白,CD109可以被特异性抗体或者酶直接标记,也可能被药物输送的定向载体识别,有望成为有效的诊断性分子标志物和药理学治疗靶点。

关键词: CD109, 胶质瘤, 耐药, 复发

Abstract: Leukocyte differentiation antigen CD109 (CD109) is a glycosylphosphatidylinositol (GPI)-associated cell surface antigen, belonging to the α-2 macroglobulin/C3, C4 and C5 super family complex, and is a transforming growth factor (TGF)-β/Smads co-receptor. CD109 regulates the occurrence and development of glioma and is closely related to drug resistance and recurrence of glioma. As a cell membrane protein, CD109 can be directly labeled by specific antibodies or enzymes, and may also be recognized by targeted vectors for drug delivery, which is expected to become an effective diagnostic molecular marker and pharmacological therapeutic target.

Key words: CD109, glioma, drug resistance, recurrence

中图分类号:

R739.41

周平慧, 曹思捷, 岳栋, 董凤云. CD109抗原在胶质瘤中的作用[J]. 基础医学与临床, 2024, 44(12): 1731-1735.

ZHOU Pinghui, CAO Sijie, YUE Dong, DONG Fengyun. The role of CD109 antigen in glioma[J]. Basic & Clinical Medicine, 2024, 44(12): 1731-1735.

参考文献

[1]Filppu P, Tanjore Ramanathan J, Granberg KJ, et al. Cd109-gp130 interaction drives glioblastoma stem cell plasticity and chemoresistance through stat3 activity[J]. JCI Insight, 2021, 6:e141486. doi: 10.1172/jci.insight.141486.
[2]Turos-Cabal M, Sanchez-Sanchez AM, Puente-Moncada N, et al. Endoplasmic reticulum regulation of glucose metabolism in glioma stem cells[J]. Int J Oncol, 2024,64:1. doi: 10.3892/ijo.2023.5589.
[3]He X, Zhang K, Liu D, et al. Predictors of seizure outcomes in patients with diffuse low-grade glioma-related epilepsy after complete glioma removal[J]. CNS Neurosci Ther, 2023, 29: 736-743.
[4]Kim JS, Shin MJ, Lee SY, et al. Cd109 promotes drug resistance in a2780 ovarian cancer cells by regulating the stat3-notch1 signaling axis[J]. Int J Mol Sci, 2023,24:10306. doi: 10.3390/ijms241210306.
[5]Hagiwara S, Sasaki E, Hasegawa Y, et al. Serum Cd109 levels reflect the node metastasis status in head and neck squamous cell carcinoma[J]. Cancer Med, 2021, 10: 1335-1346.
[6]Lin M, Sutherland DR, Horsfall W, et al. Cell surface antigen cd109 is a novel member of the alpha(2) macroglobulin/c3, c4, c5 family of thioester-containing proteins[J]. Blood, 2002, 99: 1683-1691.
[7]Xu H, Yin Y, Li Y, et al. Flot2 promotes nasopharyngeal carcinoma progression through suppression of tgf-beta pathway via facilitating cd109 expression[J]. iScience, 2023, 27:108580. doi: 10.1016/j.isci.2023.108580.
[8]Zhou S, Hassan A, Kungyal T, et al. Cd109 is a critical determinant of egfr expression and signaling, and tumorigenicity in squamous cell carcinoma cells[J]. Cancers (Basel), 2022,14:3672. doi: 10.3390/cancers14153672.
[9]Luckstadt W, Rathod M, Mobus L, et al. Cd109 drives pro-tumorigenic cell properties in human non-small cell lung cancer through interaction with desmoglein-2[J]. Res Sq, 2024:rs.3.rs-4102385. doi: 10.21203/rs.3.rs-4102385/v1.
[10]Shen K, Zhu J, Zhou S, et al. Epithelial membrane protein-3 and chitinase-3-like protein-1 as new prognostic predictors of glioma, a two-gene study[J]. Curr Oncol, 2023, 30: 8686-8702.
[11]Zheng L, He JJ, Zhao KX, et al. Expression of overall survival-emt-immune cell infiltration genes predict the prognosis of glioma[J]. Noncoding RNA Res, 2024, 9: 407-420.
[12]Jensen KT, Nielsen NS, Viana Almeida A, et al. Proteolytic cleavage of the tgfbeta co-receptor cd109 changes its conformation, resulting in protease inhibition via activation of its thiol ester, and dissociation from the cell membrane[J]. FEBS J, 2024,291:3169-3190.
[13]Cuppini L, Calleri A, Bruzzone MG, et al. Prognostic value of Cd109⁺ circulating endothelial cells in recurrent glioblastomas treated with bevacizumab and irinotecan[J]. PLoS One, 2013, 8: e74345.doi: 10.1371/journal.pone.0074345.
[14]Shiraki Y, Mii S, Enomoto A, et al. Significance of perivascular tumour cells defined by Cd109 expression in progression of glioma[J]. J Pathol, 2017, 243: 468-480.
[15]Zhang JM, Murakumo Y, Hagiwara S, et al. Cd109 attenuates tgf-beta1 signaling and enhances egf signaling in sk-mg-1 human glioblastoma cells[J]. Biochem Biophys Res Commun, 2015, 459: 252-258.
[16]Huang LH, Rau CS, Wu SC, et al. Identification and characterization of hadsc-derived exosome proteins from different isolation methods[J]. J Cell Mol Med, 2021, 25: 7436-7450.
[17]Bastola S, Pavlyukov MS, Yamashita D, et al. Glioma-initiating cells at tumor edge gain signals from tumor core cells to promote their malignancy[J]. Nat Commun, 2020, 11: 4660.doi: 10.1038/s41467-020-18189-y.
[18]Yuan H, Jiang T, Zhang WD, et al. Multiomics and bioinformatics identify differentially expressed effectors in the brain of toxoplasma gondii infected masked palm civet[J]. Front Cell Infect Microbiol, 2023, 13: 1267629.doi: 10.3389/fcimb.2023.1267629.
[19]Huang H, Shah H, Hao J, et al. Lncrna lucat1 promotes glioblastoma progression by enhancing hif1alpha activity[J]. Neuro Oncol, 2024,26:1388-1401.
[20]Minata M, Audia A, Shi J, et al. Phenotypic plasticity of invasive edge glioma stem-like cells in response to ionizing radiation[J]. Cell Rep, 2019, 26: 1893-1905 e7.
[21]Xu D, Cao M, Wang B, et al. Epigenetically regulated lncrnas dissect the intratumoural heterogeneity and facilitate immune evasion of glioblastomas[J]. Theranostics, 2023, 13: 1490-1505.
[22]Wang L, Zhou X, Chen X, et al. Enhanced therapeutic efficacy for glioblastoma immunotherapy with an oncolytic herpes simplex virus armed with anti-pd-1 antibody and il-12[J]. Mol Ther Oncol, 2024, 32: 200799.doi:10.1016/j.omton.2024.200799.
[23]Lohmeier J, Radbruch H, Brenner W, et al. Detection of recurrent high-grade glioma using microstructure characteristics of distinct metabolic compartments in a multi-modal and integrative 18f-fet pet/fast-dki approach[J]. Eur Radiol, 2024, 34: 2487-2499.
[24]Li H, Zhu J, Liu X, et al. Glioma stem cell-derived exosomes induce the transformation of astrocytes via the mir-3065-5p/dlg2 signaling axis[J]. Glia, 2024, 72: 857-871.

CD109抗原在胶质瘤中的作用

The role of CD109 antigen in glioma

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	宋丽丽, 管玉洁, 马平, 李宁. 急性髓系白血病患儿柔红霉素耐药与PD-L1蛋白表达相关[J]. 基础医学与临床, 2024, 44(6): 833-839.
[2]	张迪雅, 李云帆, 郭泓江, 仇佳星, 王钰铖, 鞠瑞, 郭磊. 胶质瘤条件培养基促进巨噬细胞糖酵解及表型转化[J]. 基础医学与临床, 2024, 44(5): 599-605.
[3]	杨铠菲, 朱静格, 张洋洋, 赵俊果, 高雨悦, 胡焕焕, 姬国杰. 索拉菲尼诱导的细胞凋亡和自噬对HeLa细胞耐药性的影响[J]. 基础医学与临床, 2024, 44(4): 467-473.
[4]	王子豪, 夏小超, 李舜. 跨膜蛋白质在恶性肿瘤中作用的研究进展[J]. 基础医学与临床, 2024, 44(3): 398-402.
[5]	张进芳, 钟明艳, 杨泉, 冯贝, 李兴东. 下调ATM/hnRNPK信号降低髓系白血病细胞阿霉素耐药[J]. 基础医学与临床, 2024, 44(12): 1638-1643.
[6]	范颖, 刘洋, 刘雁勇. 蛋白质翻译重编程在肿瘤中的研究进展[J]. 基础医学与临床, 2024, 44(12): 1736-1740.
[7]	汤蕊, 雷曙槟, 孙劲旅. 烟曲霉IgG对变应性支气管肺曲霉菌病复发的监测意义[J]. 基础医学与临床, 2023, 43(8): 1280-1283.
[8]	黄洁, 李润博, 郭建新, 韩健. DDX5和DDX17在卵巢癌组织中的表达及对人卵巢癌细胞系SKOV3增殖和耐药的影响[J]. 基础医学与临床, 2023, 43(8): 1247-1253.
[9]	施佳, 蔡成. 儿童复发性A族链球菌性扁桃体炎免疫机制的研究进展[J]. 基础医学与临床, 2023, 43(2): 336-340.
[10]	侯欣然, 厚静雅, 张亚茹, 李海丽. 叉头框蛋白M1在脑胶质瘤中作用的研究进展[J]. 基础医学与临床, 2023, 43(10): 1604-1607.
[11]	王雅晨, 张维嘉, 傅涛. 间歇性外斜视术后复发的影响因素[J]. 基础医学与临床, 2022, 42(9): 1443-1448.
[12]	赵霞, 徐薇薇, 刘益萌, 索智敏. 中国大陆地区幽门螺杆菌对常用抗生素耐药性的临床分析[J]. 基础医学与临床, 2022, 42(7): 1077-1082.
[13]	陈秋霞, 杨黎星, 马瑞, 赵永晶, 王钰铖, 鞠瑞, 郭磊. 羧胺三唑乳清酸盐抑制人胰腺癌吉西他滨耐药细胞株增殖及线粒体能量代谢[J]. 基础医学与临床, 2022, 42(4): 570-576.
[14]	何啸, 胡为杰, 吕文昌, 任玉萍, 吴敏, 吴毅平, 张奇. 环状RNA在乳腺癌中作用的研究进展[J]. 基础医学与临床, 2022, 42(3): 507-511.
[15]	刘畅, 郭向阳. 局部麻醉药物在肿瘤转移和复发中作用的研究进展[J]. 基础医学与临床, 2022, 42(3): 512-515.